NeoGenomics (NEO) Expected to Release Earnings on Wednesday

NeoGenomics (NASDAQ:NEO) is projected to issue its Q3 2026 results after the market closes on Wednesday, October 28th. Analysts expect the company to announce earnings of $0.0555 per share and revenue of $206.70 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, October 28, 2026 at 4:30 PM ET.

NeoGenomics (NASDAQ:NEO) last posted its earnings results on Tuesday, July 28th. The medical research company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of $0.03 by $0.02. The company had revenue of $201.66 million for the quarter, compared to the consensus estimate of $196.93 million. NeoGenomics had a negative return on equity of 1.99% and a negative net margin of 6.77%. NeoGenomics’s quarterly revenue was up 11.2% compared to the same quarter last year. During the same period in the previous year, the business earned $0.03 earnings per share. On average, analysts expect NeoGenomics to post ($0.09) EPS for the current fiscal year and $0.05 EPS for the next fiscal year.

NeoGenomics Price Performance

Shares of NASDAQ NEO opened at $16.69 on Tuesday. The company’s 50-day moving average price is $17.56 and its 200 day moving average price is $12.70. NeoGenomics has a 52 week low of $7.07 and a 52 week high of $20.15. The company has a debt-to-equity ratio of 0.48, a current ratio of 3.60 and a quick ratio of 3.35.

Wall Street Analyst Weigh In

NEO has been the subject of several research reports. Weiss Ratings restated a “sell (d-)” rating on shares of NeoGenomics in a research report on Monday, October 12th. Needham & Company LLC increased their target price on NeoGenomics from $19.00 to $22.00 and gave the company a “buy” rating in a report on Tuesday, October 6th. TD Cowen reiterated a “buy” rating on shares of NeoGenomics in a report on Wednesday, July 15th. Zacks Research downgraded NeoGenomics from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 28th. Finally, Craig Hallum reissued a “buy” rating and issued a $19.00 price target on shares of NeoGenomics in a report on Wednesday, July 29th. Six analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $18.17.

NeoGenomics Company Profile

NeoGenomics, Inc (NASDAQ: NEO) is a cancer-focused diagnostics company that provides laboratory testing and related services to oncologists, hospitals, academic institutions, and biopharmaceutical companies. Its diagnostic offerings support the detection, classification, and monitoring of cancer and help inform treatment decisions.

The company’s services include pathology, immunohistochemistry, flow cytometry, cytogenetics, molecular testing, and other specialized oncology assays. NeoGenomics also provides clinical trial and pharmaceutical services, including biomarker testing, central laboratory support, and companion diagnostic development for drug developers.

Founded in 1999, NeoGenomics has expanded through internal growth and acquisitions and operates a network of clinical laboratories serving customers primarily in the United States, with additional international capabilities.